☰

Andrew J. Alt, Ph.D. - Publications

Affiliations: 
University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
behavioral pharmacology
Tree Info Grants Similar researchers PubMed Report error

28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Olson KM, Campbell A, Alt A, Traynor JR. Finding the Perfect Fit: Conformational Biosensors to Determine the Efficacy of GPCR Ligands. Acs Pharmacology & Translational Science. 5: 694-709. PMID 36110374 DOI: 10.1021/acsptsci.1c00256  0.424
2021 Kandasamy R, Hillhouse TM, Livingston KE, Kochan KE, Meurice C, Eans SO, Li MH, White AD, Roques BP, McLaughlin JP, Ingram SL, Burford NT, Alt A, Traynor JR. Positive allosteric modulation of the mu-opioid receptor produces analgesia with reduced side effects. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33846240 DOI: 10.1073/pnas.2000017118  0.557
2019 Scott CE, Tang Y, Alt A, Burford NT, Gerritz SW, Ogawa LM, Zhang L, Kendall DA. Identification and biochemical analyses of selective CB agonists. European Journal of Pharmacology. PMID 30951717 DOI: 10.1016/J.Ejphar.2019.03.054  0.542
2017 Livingston KE, Stanczyk MA, Burford N, Alt A, Canals M, Traynor JR. Pharmacological Evidence for a Putative Conserved Allosteric Site on Opioid Receptors. Molecular Pharmacology. PMID 29233847 DOI: 10.1124/Mol.117.109561  0.649
2017 Carpenter J, Wang Y, Wu G, Feng J, Ye XY, Morales CL, Broekema M, Rossi KA, Miller KJ, Murphy BJ, Wu GY, Malmstrom SE, Azzara AV, Sher PM, Fevig JM, ... Alt A, et al. Utilization of an active site mutant receptor for the identification of potent and selective atypical 5-HT2C receptor agonists. Journal of Medicinal Chemistry. PMID 28635286 DOI: 10.1021/Acs.Jmedchem.7B00385  0.446
2017 Winters BL, Gregoriou GC, Kissiwaa SA, Wells OA, Medagoda DI, Hermes SM, Burford NT, Alt A, Aicher SA, Bagley EE. Endogenous opioids regulate moment-to-moment neuronal communication and excitability. Nature Communications. 8: 14611. PMID 28327612 DOI: 10.1038/ncomms14611  0.445
2016 Alt A. Overview of Critical Parameters for the Design and Execution of a High-Throughput Screen for Allosteric Ligands. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. 74: 9.20.1-9.20.23. PMID 27636112 DOI: 10.1002/cpph.12  0.301
2016 Shang Y, Yeatman HR, Provasi D, Alt A, Christopoulos A, Canals M, Filizola M. Proposed Mode of Binding and Action of Positive Allosteric Modulators at Opioid Receptors. Acs Chemical Biology. PMID 26841170 DOI: 10.1021/Acschembio.5B00712  0.534
2015 Alt A, Pendri A, Bertekap RL, Li G, Benitex Y, Nophsker M, Rockwell KL, Burford NT, Sum CS, Chen J, Herbst JJ, Ferrante M, Hendricson A, Cvijic ME, Westphal R, et al. Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors. The Journal of Pharmacology and Experimental Therapeutics. PMID 26582730 DOI: 10.1124/jpet.115.226910  0.389
2015 Bisignano P, Burford NT, Shang Y, Marlow B, Livingston KE, Fenton AM, Rockwell K, Budenholzer L, Traynor JR, Gerritz SW, Alt A, Filizola M. Ligand-Based Discovery of a New Scaffold for Allosteric Modulation of the μ-Opioid Receptor. Journal of Chemical Information and Modeling. PMID 26347990 DOI: 10.1021/Acs.Jcim.5B00388  0.585
2015 Burford NT, Livingston KE, Canals M, Ryan MR, Budenholzer LM, Han Y, Shang Y, Herbst JJ, O'Connell J, Banks M, Zhang L, Filizola M, Bassoni DL, Wehrman TS, Christopoulos A, ... ... Alt A, et al. Discovery, Synthesis, and Molecular Pharmacology of Selective Positive Allosteric Modulators of the δ-Opioid Receptor. Journal of Medicinal Chemistry. 58: 4220-9. PMID 25901762 DOI: 10.1021/Acs.Jmedchem.5B00007  0.611
2014 Burford NT, Wehrman T, Bassoni D, O'Connell J, Banks M, Zhang L, Alt A. Identification of selective agonists and positive allosteric modulators for µ- and δ-opioid receptors from a single high-throughput screen. Journal of Biomolecular Screening. 19: 1255-65. PMID 25047277 DOI: 10.1177/1087057114542975  0.539
2014 Zhu Y, Watson J, Chen M, Shen DR, Yarde M, Agler M, Burford N, Alt A, Jayachandra S, Cvijic ME, Zhang L, Dyckman A, Xie J, O'Connell J, Banks M, et al. Integrating High-Content Analysis into a Multiplexed Screening Approach to Identify and Characterize GPCR Agonists. Journal of Biomolecular Screening. 19: 1079-1089. PMID 24789006 DOI: 10.1177/1087057114533146  0.343
2013 Martinez-Perez JA, Iyengar S, Shannon HE, Bleakman D, Alt A, Clawson DK, Arnold BM, Bell MG, Bleisch TJ, Castaño AM, Del Prado M, Dominguez E, Escribano AM, Filla SA, Ho KH, et al. GluK1 antagonists from 6-(tetrazolyl)phenyl decahydroisoquinoline derivatives: in vitro profile and in vivo analgesic efficacy. Bioorganic & Medicinal Chemistry Letters. 23: 6463-6. PMID 24140446 DOI: 10.1016/J.Bmcl.2013.09.045  0.341
2013 Burford NT, Clark MJ, Wehrman TS, Gerritz SW, Banks M, O'Connell J, Traynor JR, Alt A. Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proceedings of the National Academy of Sciences of the United States of America. 110: 10830-5. PMID 23754417 DOI: 10.1073/pnas.1300393110  0.641
2012 Noblin DJ, Bertekap RL, Burford NT, Hendricson A, Zhang L, Knox R, Banks M, O'Connell J, Alt A. Development of a high-throughput calcium flux assay for identification of all ligand types including positive, negative, and silent allosteric modulators for G protein-coupled receptors. Assay and Drug Development Technologies. 10: 457-67. PMID 22746835 DOI: 10.1089/Adt.2011.443  0.345
2011 Burford NT, Watson J, Bertekap R, Alt A. Strategies for the identification of allosteric modulators of G-protein-coupled receptors. Biochemical Pharmacology. 81: 691-702. PMID 21184747 DOI: 10.1016/j.bcp.2010.12.012  0.526
2007 Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE, Witkin JM. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology. 52: 1482-7. PMID 17418283 DOI: 10.1016/J.Neuropharm.2007.02.005  0.448
2007 Dolman NP, More JC, Alt A, Knauss JL, Pentikäinen OT, Glasser CR, Bleakman D, Mayer ML, Collingridge GL, Jane DE. Synthesis and pharmacological characterization of N3-substituted willardiine derivatives: role of the substituent at the 5-position of the uracil ring in the development of highly potent and selective GLUK5 kainate receptor antagonists. Journal of Medicinal Chemistry. 50: 1558-70. PMID 17348638 DOI: 10.1021/Jm061041U  0.349
2006 Jones CK, Alt A, Ogden AM, Bleakman D, Simmons RM, Iyengar S, Dominguez E, Ornstein PL, Shannon HE. Antiallodynic and antihyperalgesic effects of selective competitive GLUK5 (GluR5) ionotropic glutamate receptor antagonists in the capsaicin and carrageenan models in rats. The Journal of Pharmacology and Experimental Therapeutics. 319: 396-404. PMID 16837561 DOI: 10.1124/Jpet.106.105601  0.369
2006 Weiss B, Alt A, Ogden AM, Gates M, Dieckman DK, Clemens-Smith A, Ho KH, Jarvie K, Rizkalla G, Wright RA, Calligaro DO, Schoepp D, Mattiuz EL, Stratford RE, Johnson B, et al. Pharmacological characterization of the competitive GLUK5 receptor antagonist decahydroisoquinoline LY466195 in vitro and in vivo. The Journal of Pharmacology and Experimental Therapeutics. 318: 772-81. PMID 16690725 DOI: 10.1124/Jpet.106.101428  0.361
2006 Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology. 185: 240-7. PMID 16470401 DOI: 10.1007/S00213-005-0292-0  0.361
2006 Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochemical Pharmacology. 71: 1273-88. PMID 16442080 DOI: 10.1016/J.Bcp.2005.12.022  0.405
2005 Dolman NP, Troop HM, More JC, Alt A, Knauss JL, Nistico R, Jack S, Morley RM, Bortolotto ZA, Roberts PJ, Bleakman D, Collingridge GL, Jane DE. Synthesis and pharmacology of willardiine derivatives acting as antagonists of kainate receptors. Journal of Medicinal Chemistry. 48: 7867-81. PMID 16302825 DOI: 10.1021/jm050584l  0.447
2005 Dominguez E, Iyengar S, Shannon HE, Bleakman D, Alt A, Arnold BM, Bell MG, Bleisch TJ, Buckmaster JL, Castano AM, Del Prado M, Escribano A, Filla SA, Ho KH, Hudziak KJ, et al. Two prodrugs of potent and selective GluR5 kainate receptor antagonists actives in three animal models of pain. Journal of Medicinal Chemistry. 48: 4200-3. PMID 15974569 DOI: 10.1021/Jm0491952  0.409
2004 More JC, Nistico R, Dolman NP, Clarke VR, Alt AJ, Ogden AM, Buelens FP, Troop HM, Kelland EE, Pilato F, Bleakman D, Bortolotto ZA, Collingridge GL, Jane DE. Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist. Neuropharmacology. 47: 46-64. PMID 15165833 DOI: 10.1016/J.Neuropharm.2004.03.005  0.431
2002 Alt A, Clark MJ, Woods JH, Traynor JR. Mu and Delta opioid receptors activate the same G proteins in human neuroblastoma SH-SY5Y cells. British Journal of Pharmacology. 135: 217-25. PMID 11786497 DOI: 10.1038/Sj.Bjp.0704430  0.48
2000 Remmers AE, Clark MJ, Alt A, Medzihradsky F, Woods JH, Traynor JR. Activation of G protein by opioid receptors: role of receptor number and G-protein concentration. European Journal of Pharmacology. 396: 67-75. PMID 10822058 DOI: 10.1016/S0014-2999(00)00212-0  0.487
Show low-probability matches.